INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 11, 2023 |
Director, Bd. Co-Chair, President & CSO
Trans History: 628
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,155 | -- | 765,327 |
| Dec 11, 2023 |
Director, Bd. Co-Chair, President & CSO
Trans History: 628
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,155 | -- | -- |
| Dec 11, 2019 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,155 | -- | 25,155 |
| Dec 11, 2019 |
Director, President and CSO
Trans History: 628
|
Director, President and CSO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,155 | -- | 25,155 |
| May 02, 2012 |
SVP Finance and Admin CFO Trea
Trans History: 645
|
SVP Finance and Admin CFO Trea | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,438 | $21.92 | 105,604 |
| May 02, 2012 |
SVP Finance and Admin CFO Trea
Trans History: 645
|
SVP Finance and Admin CFO Trea | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,438 | -- | 29,000 |
| Feb 21, 2012 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,438 | $21.92 | 72,378 |
| Feb 21, 2012 |
SVP Clinical Development & Reg
Trans History: 208
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,438 | -- | -- |
| Jan 10, 2012 |
VP Regulatory Development and
Trans History: 288
|
VP Regulatory Development and | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,438 | $21.92 | 86,582 |
| Jan 10, 2012 |
VP Regulatory Development and
Trans History: 288
|
VP Regulatory Development and | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,438 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.